Our flagship product is the first and only urine test for colorectal cancer screening.
As the second leading cause of cancer-related deaths in the United States, and the third most common cancer worldwide, colorectal cancer is a major public health concern. There is an urgent need for a more patient-friendly, accurate and inexpensive population-based screening test for colorectal cancer.
Our flagship product, PolypDx™, is the first and only urine-based test that detects both colorectal cancer and its precursors – adenomatous polyps. Current fecal-based tests have low screening compliance and do not necessarily detect precancerous polyps. Our test is an easy-to-complete, user-friendly test, designed for maximum patient acceptability. PolypDx™ provides doctors with a new tool for early screening and detection, enabling the timely removal of polyps before they progress to colorectal cancer.
Competitive Advantages of PolypDx™
Early stage detection - PolypDx™ detects adenomatous polyps, the precursor to colorectal cancer, thereby detecting individuals at risk for colorectal cancer.
High patient compliance - PolypDx™ does not require any unpleasant bowel cleansing preparation, nor unsanitary handling of stool, and does not have any health risks.
Ease of use -PolypDx™ is fast and simple – just a small urine sample is required.
Higher accuracy - PolypDx™ has superior performance characteristics for colonic adenomatous polyp detection. PolypDx™ was validated in clinical trial of nearly 1000 patients, demonstrating a higher sensitivity than fecal based tests (FOBT/FIT) for detecting adenomatous polyps.
Cost-effective and high-throughput platform - PolypDx™ is a Mass-Spectometer-based test, therefore allowing high-throughput and cost-effective population-based screening for those between 50 and 74 years.
PolypDx™ was first launched as a Laboratory Developed Test focused on the detection of adenomatous polyps. We have since incorporated additional metabolomic biomarkers for colorectal cancer and are planning a US pivotal trial that will include the expanded indication.
Our metabolomics technology platform is leading to exciting new pipeline products. We are working on developing and validating less invasive, more sensitive diagnostic tests and point of care technologies.
We are working with clinical experts in world class institutions that help guide us in developing relevant technologies.
Want to be part of our story? If you are interested in working with us, reach out.